AN2 Therapeutics (ANTX) EBITDA (2021 - 2026)
AN2 Therapeutics (ANTX) reported EBITDA of -$10.1 million for Q1 2026, up 5.1% year-over-year from -$9.6 million in Q1 2025, and down 15.75% quarter-over-quarter from -$8.7 million in Q4 2025.
AN2 Therapeutics (ANTX) EBITDA (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of EBITDA data on file, last reported at -$10.1 million in Q1 2026.
- EBITDA for Q1 2026 came in at -$10.1 million, up 5.1% year-over-year; the trailing twelve-month figure through Mar 2026 was -$34.6 million (up 23.7% YoY), and the FY2025 annual result was -$35.1 million, up 31.84% from the prior year.
- EBITDA fell to -$10.1 million in Q1 2026 per ANTX's latest filing, from -$8.7 million in the prior quarter.
- Over five years, EBITDA peaked at -$6.5 million in Q2 2025 and troughed at -$16.8 million in Q1 2024.
- A 5-year average of -$11.9 million and a median of -$11.5 million in 2022 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2025: EBITDA plunged 280.18% in 2022, then surged 55.32% in 2025.
- A 5-year view of EBITDA shows it stood at -$11.7 million in 2022, then sank by 41.34% to -$16.5 million in 2023, then soared by 53.92% to -$7.6 million in 2024, then fell by 14.65% to -$8.7 million in 2025, then slipped by 15.75% to -$10.1 million in 2026.
- Business Quant data shows ANTX's EBITDA at -$10.1 million in Q1 2026, -$8.7 million in Q4 2025, and -$9.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.44 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -65.83 Mn |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - | -10.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.09 Mn |
| Dec 31, 2025 | -8.72 Mn |
| Sep 30, 2025 | -9.31 Mn |
| Jun 30, 2025 | -6.49 Mn |
| Mar 31, 2025 | -10.63 Mn |
| Dec 31, 2024 | -7.60 Mn |
| Sep 30, 2024 | -12.61 Mn |
| Jun 30, 2024 | -14.52 Mn |
| Mar 31, 2024 | -16.84 Mn |
| Dec 31, 2023 | -16.50 Mn |
| Sep 30, 2023 | -16.71 Mn |
| Jun 30, 2023 | -15.75 Mn |
| Mar 31, 2023 | -15.12 Mn |
| Dec 31, 2022 | -11.68 Mn |
| Sep 30, 2022 | -11.52 Mn |
| Jun 30, 2022 | -10.32 Mn |
| Mar 31, 2022 | -7.79 Mn |
| Dec 31, 2021 | -7.57 Mn |
| Sep 30, 2021 | -6.95 Mn |
| Jun 30, 2021 | -5.01 Mn |